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Introduction 
 Alzheimer’s disease is a neurodegenerative disease caused by the 
incorrect cleaving of the transmembrane Amyloid Precursor Protein into the 
neurotoxic Aβ40 and Aβ42 fragments
2. These fragments are soluble oligomers 
with a random coil conformation that can impair synapses or 
neurotransmission; they may also aggregate into parallel and antiparallel 
beta sheets to form amyloid plaques, which can block or distort signaling 
between neuronal pathways7. 
 
 Aβ fibrils self-assemble into parallel and antiparallel beta sheets on 
hydrophobic graphite, but not on hydrophilic mica5,6. Aβ fibrils also assemble 
on graphene, which irreversibly captures fibrils3, suggesting graphene might 
have a role in the study of Alzheimer’s amyloid plaque. 
 
 These studies characterize binding between amyloid beta peptide 
fibrils and graphene using Raman spectroscopy, scanning electron 
microscopy (SEM), and circular dichroism (CD). The goal is to provide 
evidence that graphene can attract free floating Aβ fibrils and Aβ plaque. 
Both studies currently use diphenylalanine peptide, a self-assembling model 
peptide for Aβ fibrils. 
-For the SEM, a stock solution of diphenylalanine dissolved in 1,1,1,3,3,3-
hexafluouro-2-propanol (HFIP) (100 mg/mL) was added to graphene dispersed 
in 7x TE (1 mg/mL). All samples were dried on aluminum stubs  coated with 
gold. A total of fourteen samples were analyzed.  -Samples 1 and 2 were the 
stock graphene and diphenylalanine solutions. Samples 3-14 were three sets of 
four samples each. The 1st of a set was not shaken; the 2nd was hand shaken; 
the 3rd was vortex shaken; the 4th was sonicated. -Samples 2-6 had a 1:1 ratio 
of graphene and diphenylalanine; samples 7-10 had a 2:1 ratio; samples 11-14 
had a 1:2 ratio. FF nanotubes structures are characterized by two strong, 
positive bands, with one located around 200nm and the second appearing 
around 220nm. A local, positive minimum is located between  the two 
strongly positive bands and occurs around 209nm. Finally, a strong negative 
band is located below 195nm, also representing a global spectral minimum. 
Changes in the ellipticity intensity would therefore represent a modulation of 
nanotubes character, either in an increasing or decreasing capacity.  
 
Experiment 1 explored if diphenylalanine easily bound to graphene dispersed 
in 7xTE, which is ideal for keeping graphene powder in an even suspension 
within a solution. Graphene did bind to diphenylalanine, with a higher binding 
rate in a 2:1 gr:diphe ratio, but otherwise the binding efficacy was seemingly 
random and unreliable. Furthermore, the reference article4 found ideal 
binding occurred in the 3.7-5.4 pH range. This study’s samples had a 7.3 pH 
to mimic cerebrospinal fluid. 
 
Experiment 2  CD spectral scans with the increase in the GO concentration 
reveal a modulation of nanotubes character relative to FF control samples 
(0.4mg/ml FF, 0mg/ml GO)suggestive of FF-GO nanocomposite formation. 
Samples with FF:GO ratios of 1:2 and 1:4 demonstrated an increase in 
ellipticity intensity at both diagnostic wavelengths. These increase in the 
quantity of nanotubes upon addition of GO, suggests the formation of 
peptide-GO nanocomposite.  
 
These experiments have demonstrated that there are binding capabilities 
between graphene & graphene oxide and diphenylalanine, even in less than 
ideal situations. Diphenylalanine was chosen because its two phenylalanines 
mimic those in amyloid beta peptides.  
Experiment 1 
Signs of binding include fanned out or twisted cylinders with graphene “scales” or “ridges” on 
them. All samples were prevalently graphene with no observable effect from diphenylalanine. 
 
 
 
 
 
 
 
 
 
        Graphene powder at x1000 under the SEM.               Graphene in 7x TE (1 mg/mL) at x1000 under the SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Sample 10: 2:1 gr:diphe, sonicated at x300. The fanned out        Sample 8: 2:1 gr:diphe, hand shaken at x30. There are 
        cylinders are circled in red. The twisted cylinders are               twisted cylinders all over the surface, some circled in blue. 
        circled in blue. Some droplets of gold left by SEM 
        preparation are circled in yellow. The rest is graphene. 
 
Experiment 2 
The diphenylalanine and GO samples self-assembled into nanotube.  
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
  
 
 
 
 
 
 
         
The next step is to recreate an aqueous graphene dispersion using a 
modified Hummers method4 and determine if it is a better medium for 
diphenylalanine binding than 7x TE, since 7x TE is a possible deterrent of 
binding, and ddH20 is a possible enabler. Once the more productive 
dispersion solution is determined, we will experiment the conditions of 
binding between graphene and amyloid beta peptide, whether in random coil 
or beta sheet conformation. The pH will remain comparable to that of 
cerebrospinal fluid. 
Afterwards, experimentation of amyloid beta peptide to graphene will be done 
in artificial cerebrospinal fluid to determine how the extracellular fluid in the 
brain may change the reactions between Aβ and graphene. I 
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